Symptomatic Obstructive Hypertrophic Cardiomyopathy research hub
3 indexed studies · 2 currently recruiting
- recruitingPhase III and phase IV (Integrated)
MEMENTO-A Phase 3b/4 Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to assess the impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging (CMR)
This study is looking at a new medicine called mavacamten for adults with a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It aims to see if the medicine can reduce the thickness of the heart walls and the size of the heart's upper chambers.
Hungary · Finland · Spain - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
This study is testing a new medicine, Aficamten, for people with a heart condition called obstructive hypertrophic cardiomyopathy. It compares Aficamten to a common medicine, Metoprolol, to see if it helps patients feel better and improve how well their heart works. Researchers want to know if it's safe and effective.
Denmark · Italy · Hungary - active not recruitingPHASE2, PHASE3
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
This study is looking into a new medicine called Aficamten for young people aged 12-17 with a heart condition called hypertrophic cardiomyopathy (oHCM). It aims to see if the medicine is safe and effective in improving their symptoms, compared to a dummy medicine.
United States · Canada · Italy